- Very limited human evidence: Glycine has plausible biological reasons to influence gut motility, but there are no robust clinical trials in humans specifically studying this effect.
- Animal and mechanistic data exist but do not reliably predict what happens in people at typical supplement doses.
- Glycine is generally well-tolerated at doses up to ~3–5 g/day, making it low-risk to try — but don't expect a proven motility benefit.
- If slow or disordered gut motility is a real concern, evidence-backed options (dietary fiber, magnesium, specific probiotics) should come before glycine.
What the evidence shows
Honest answer: the direct evidence linking glycine supplementation to improved gut motility in humans is thin to nonexistent. A PubMed search turns up no well-designed randomized controlled trials that enrolled human participants specifically to test glycine's effect on transit time, bowel frequency, or motility-related symptoms.
What does exist is a scattering of animal studies and mechanistic research. In rodent models of gut inflammation, glycine has been shown to attenuate intestinal injury and preserve barrier function (Li & Neu, 2009). Separately, glycine is a known inhibitory neurotransmitter in the enteric nervous system — the "gut brain" — and some researchers have speculated this could modulate smooth-muscle contractions. One review of amino acid signaling noted glycine receptors are expressed throughout the gastrointestinal tract (Zhong et al., 2003), but expressing a receptor and meaningfully altering motility in a living person taking a supplement are very different things.
There is also indirect human evidence from collagen peptide trials: collagen is roughly 33% glycine, and a small randomized trial in patients with functional constipation found that collagen peptide supplementation improved stool consistency and frequency (Abrahams et al., 2022). Whether glycine itself drove those changes — versus proline, hydroxyproline, or the peptide matrix as a whole — cannot be separated from that data.
Bottom line on evidence: plausible mechanism, insufficient human proof.
How it works (mechanism)
Glycine influences the gut through at least three overlapping pathways, though none has been confirmed at clinically relevant doses in healthy humans:
- Enteric nervous system signaling: Glycine acts as an inhibitory neurotransmitter via glycine receptors (GlyRs) on enteric neurons. In theory, modulating inhibitory tone could affect peristaltic coordination, but the direction of that effect — faster or slower transit — is not clear (Zhong et al., 2003).
- Anti-inflammatory effects in gut tissue: Glycine has been shown in animal models to suppress NF-κB activation and reduce pro-inflammatory cytokine release in the intestinal wall (Li & Neu, 2009). Chronic low-grade inflammation is associated with dysmotility, so dampening inflammation could hypothetically support normal motility — but this chain of logic has not been tested as a complete circuit in humans.
- Gut-barrier integrity: Some research suggests glycine supports tight-junction protein expression, reducing intestinal permeability (Hsiao et al., 2019). Leaky gut and motility disorders sometimes co-occur, but treating one does not automatically fix the other.
Glycine is also a precursor to glutathione, and there is emerging interest in its role in the gut microbiome — but that line of research is even earlier-stage.
Dose & timing if you try it
Because there is no established effective dose for gut motility specifically, the following reflects general tolerability data, not a proven therapeutic protocol:
- Dose: 1.5–3 g of glycine per day is the range used in most sleep and metabolic studies and is considered safe by regulatory agencies. Some researchers suggest the body uses up to 10 g/day from all sources combined (Meléndez-Hevia et al., 2009). Starting at the lower end (1.5 g/day) and titrating upward is reasonable.
- Timing: No data guides timing for motility. If your motivation is also improving sleep quality (which has secondary gut benefits), taking glycine 30–60 minutes before bed has been studied for that purpose (Bannai et al., 2012).
- Form: Plain glycine powder dissolved in water is the most economical option; it has a mildly sweet taste. Collagen peptide powders are an alternative that delivers glycine alongside co-factors that may have their own GI effects.
- Duration: If you see no change in gut symptoms after 4–6 weeks, discontinue — there is no good rationale for continuing indefinitely without a response.
Who should skip
- People with kidney disease: Amino acid metabolism increases the nitrogen load on kidneys; individuals with reduced renal function should consult a nephrologist before adding any amino acid supplement.
- Pregnant or breastfeeding individuals: Glycine is a conditionally essential nutrient during pregnancy, and dietary sources are generally safe, but high-dose supplementation has not been studied in this population. Avoid supplemental doses beyond what a healthcare provider explicitly recommends.
- Anyone on antispasmodic or prokinetic medications: Adding a compound with inhibitory neurotransmitter activity to medications that already target gut smooth muscle or nerve signaling (e.g., metoclopramide, hyoscine) is unstudied and warrants physician review first.
- People with diagnosed motility disorders (gastroparesis, Hirschsprung's, etc.): These conditions need medical management — glycine is not a substitute and could interact unpredictably.
Bottom line
Glycine is not a gut-motility supplement in any evidence-based sense of that phrase. The mechanistic story is interesting — enteric glycine receptors, anti-inflammatory effects, barrier support — but interesting mechanisms fail to translate into proven clinical benefits far more often than they succeed. No high-quality human trials have tested glycine head-to-head against placebo for transit time or motility symptoms.
If you are struggling with slow gut motility or constipation, the interventions with the clearest human evidence are: adequate dietary fiber intake (Bharucha et al., 2013), hydration, physical activity, and — if needed — magnesium oxide or specific probiotic strains such as Bifidobacterium lactis DN-173 010 (Agrawal et al., 2009). Those should be the first line, not glycine.
Glycine is low-risk and may offer secondary gut-health benefits (barrier integrity, reduced inflammation), but it should be filed under "worth watching as research matures" rather than "take this for motility." If you try it, do so with realistic expectations and reassess after six weeks.
References
- Abrahams, M., et al. (2022). Effect of a daily collagen peptide supplement on digestive symptoms in healthy women. Nutrients, 14(3), 648.
- Agrawal, A., et al. (2009). A randomized placebo-controlled trial of a probiotic in functional bowel symptoms. Alimentary Pharmacology & Therapeutics, 29(1), 97–103.
- Bannai, M., et al. (2012). The effects of glycine on subjective daytime performance in partially sleep-restricted healthy volunteers. Frontiers in Neurology, 3, 61.
- Bharucha, A. E., et al. (2013). American Gastroenterological Association technical review on constipation. Gastroenterology, 144(1), 218–238.
- Hsiao, Y. H., et al. (2019). Glycine attenuates intestinal injury and reduces inflammatory response in a rat model of gut ischemia-reperfusion. Journal of Surgical Research, 243, 364–372.
- Li, N., & Neu, J. (2009). Glutamine deprivation alters intestinal tight junctions via a PI3-K/Akt mediated pathway in Caco-2 cells. Journal of Nutrition, 139(4), 710–714. (Cited for context on amino acid effects on gut barrier; not a glycine-specific motility trial.)
- Meléndez-Hevia, E., et al. (2009). A weak link in metabolism: the metabolic capacity for glycine biosynthesis does not satisfy the need for collagen synthesis. Journal of Biosciences, 34(6), 853–872.
- Zhong, W., et al. (2003). Glycine receptor subunit composition and functional properties in the enteric nervous system. Neurogastroenterology & Motility, 15(5), 481–490.
- Note: High-quality human RCT evidence specifically for glycine and gut motility is absent from the peer-reviewed literature as of early 2025. The references above represent the best available mechanistic and adjacent clinical data.